{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:17:45Z","timestamp":1789834665610,"version":"4.0.1"},"reference-count":52,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Despite having normal growth hormone (GH) secretion, individuals with Turner syndrome (TS) have short stature. Treatment with recombinant human GH is recommended for TS girls with short stature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This work aimed to evaluate the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Secondary analysis was conducted of Norditropin data from 2 non-interventional studies: NordiNet\u00ae IOS (NCT00960128) and the ANSWER program (NCT01009905).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2377 girls with TS were included in the safety analysis set (SAS), with 1513 in the treatment-naive effectiveness analysis set (EAS). At the start of treatment, 1273 (84%) participants were prepubertal (EAS); mean (SD) age was 8.8 (3.9) years. Mean (SD) dose received at the start of GH treatment was 0.045 (0.011) mg\/kg\/day (EAS). Mean (SD) baseline insulin-like growth factor-1 (IGF-I) SD score (SDS) was \u22120.86 (1.52), and mean (SD) duration of GH treatment (SAS) was 3.8 (2.8) years.<\/jats:p>\n                    <jats:p>Height SDS (HSDS) increased throughout follow-up, with near-adult HSDS reached by 264 (17%) participants (mean [SD] \u22121.99 [0.94]; change from baseline +0.90 [0.85]). During the study, 695 (46%) participants (EAS) entered puberty at a mean (SD) age of 12.7 (1.9) years (whether puberty was spontaneous or induced was unknown). Within the SAS, mean IGF-I SDS (SD) at year 10 was 0.91 (1.69); change from baseline +1.48 (1.70). Serious adverse reactions were reported in 10 participants (epiphysiolysis [n = 3]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GH-treated participants with TS responded well, without new safety concerns. Our real-world data are in agreement with previous studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad159","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T15:59:45Z","timestamp":1679500785000},"page":"2653-2665","source":"Crossref","is-referenced-by-count":9,"title":["Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet\u00ae IOS and Answer Program"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-9520","authenticated-orcid":false,"given":"Philippe","family":"Backeljauw","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine , Cincinnati, OH 45229-3039 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne C","family":"Blair","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Alder Hey Children's NHS Foundation Trust , Liverpool L14 5AB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Ferran","sequence":"additional","affiliation":[{"name":"Qualiance ApS , 1663 Copenhagen V , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Kelepouris","sequence":"additional","affiliation":[{"name":"Novo Nordisk Inc , Plainsboro, NJ 08536 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, M Health Fairview Masonic Children's Hospital , Minneapolis, MN 55454 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pietropoli","sequence":"additional","affiliation":[{"name":"Novo Nordisk Health Care AG , 8050 Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Polak","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9, H\u00f4pital Universitaire Necker Enfants Malades, Assistance Publique H\u00f4pitaux de Paris , 75015 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"S\u00e4vendahl","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Karolinska University Hospital , 171 64 Solna , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franciska","family":"Verlinde","sequence":"additional","affiliation":[{"name":"Belgian Society for Pediatric Endocrinology and Diabetology , 1090 Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman R","family":"Rohrer","sequence":"additional","affiliation":[{"name":"University Children\u2019s Hospital, Saarland University Medical Center , 66421 Homburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"issue":"1","key":"2023091800470772700_dgad159-B1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01213097","article-title":"Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark","volume":"87","author":"Nielsen","year":"1991","journal-title":"Hum Genet"},{"issue":"10","key":"2023091800470772700_dgad159-B2","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1210\/jc.2006-0558","article-title":"Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome","volume":"91","author":"Stochholm","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023091800470772700_dgad159-B3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jc.2007-1723","article-title":"Long-term safety of recombinant human growth hormone in Turner syndrome","volume":"93","author":"Bolar","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023091800470772700_dgad159-B4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2006-1374","article-title":"Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group","volume":"92","author":"Bondy","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023091800470772700_dgad159-B5","first-page":"CD003887","article-title":"Recombinant growth hormone for children and adolescents with Turner syndrome","author":"Baxter","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2023091800470772700_dgad159-B6","doi-asserted-by":"crossref","first-page":"737893","DOI":"10.3389\/fendo.2021.737893","article-title":"GH responsiveness in children with Noonan syndrome compared to Turner syndrome","volume":"9","author":"Dahlgren","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2023091800470772700_dgad159-B7","first-page":"1439","article-title":"Circulating growth hormone isoforms in girls with Turner's syndrome","volume":"78","author":"Blethen","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023091800470772700_dgad159-B8","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1210\/jc.2004-2187","article-title":"Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial","volume":"90","author":"Stephure","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023091800470772700_dgad159-B9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF03347202","article-title":"Adult height in sixty girls with Turner syndrome treated with growth hormone matched with an untreated group","volume":"28","author":"Pasquino","year":"2005","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2023091800470772700_dgad159-B10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ecl.2012.08.007","article-title":"Update on Turner and Noonan syndromes","volume":"41","author":"Chacko","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023091800470772700_dgad159-B11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000316130","article-title":"Current indications for growth hormone therapy for children and adolescents","volume":"18","author":"Richmond","year":"2010","journal-title":"Endocr Dev"},{"issue":"6","key":"2023091800470772700_dgad159-B12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1159\/000500780","article-title":"Final adult height after growth hormone treatment in patients with Turner syndrome","volume":"91","author":"Ahn","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"2023091800470772700_dgad159-B13","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1210\/jc.2019-00775","article-title":"Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet\u00ae IOS and ANSWER program","volume":"104","author":"S\u00e4vendahl","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2023091800470772700_dgad159-B14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/CLEP.S42602","article-title":"The NordiNet\u00ae international outcome study and NovoNet\u00ae ANSWER program\u00ae: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin\u00ae)","volume":"5(1)","author":"H\u00f6ybye","year":"2013","journal-title":"Clin Epidemiol"},{"issue":"1","key":"2023091800470772700_dgad159-B15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13633-015-0015-1","article-title":"Noonan syndrome and Turner syndrome patients respond similarly to 4 years\u2019 growth-hormone therapy: longitudinal analysis of growth-hormone-naive patients enrolled in the NordiNet(R) International Outcome Study and the ANSWER program","volume":"2015","author":"Lee","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"issue":"2","key":"2023091800470772700_dgad159-B16","first-page":"53","article-title":"Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study","volume":"60","author":"Brabant","year":"2003","journal-title":"Horm Res"},{"key":"2023091800470772700_dgad159-B17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1651-2227.1988.tb10796.x","article-title":"Spontaneous growth in Turner's syndrome","volume":"343","author":"Ranke","year":"1988","journal-title":"Acta Paediatr Scand Suppl"},{"issue":"4","key":"2023091800470772700_dgad159-B18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0929-693X(96)84683-5","article-title":"Turner syndrome: spontaneous growth of stature, weight increase and accelerated bone maturation [article in French]","volume":"3","author":"Cabrol","year":"1996","journal-title":"Arch Pediatr"},{"issue":"9","key":"2023091800470772700_dgad159-B19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1651-2227.1997.tb15174.x","article-title":"Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH treatment","volume":"86","author":"Westerlaken C","year":"1997","journal-title":"Acta Paediatr"},{"key":"2023091800470772700_dgad159-B20","author":"Backeljauw"},{"key":"2023091800470772700_dgad159-B21","author":"WHO Multicentre Growth Reference Study Group"},{"issue":"6","key":"2023091800470772700_dgad159-B22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-3476(69)80224-6","article-title":"Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation","volume":"74","author":"Usher","year":"1969","journal-title":"J Pediatr"},{"issue":"8","key":"2023091800470772700_dgad159-B23","first-page":"2534","article-title":"Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation","volume":"80","author":"Juul","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023091800470772700_dgad159-B24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000333073","article-title":"Impact of age and duration of growth hormone therapy in children with Turner syndrome","volume":"76","author":"Ross","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"9","key":"2023091800470772700_dgad159-B25","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1210\/jc.2006-2874","article-title":"Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial","volume":"92","author":"Davenport","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2 Pt 3","key":"2023091800470772700_dgad159-B26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1542\/peds.102.S3.479","article-title":"Growth hormone treatment of girls with Turner syndrome: the National Cooperative Growth Study experience","volume":"102","author":"Plotnick","year":"1998","journal-title":"Pediatrics"},{"issue":"6","key":"2023091800470772700_dgad159-B27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000181910","article-title":"Three-year results of treatment with growth hormone, alone or associated with oxandrolone, in girls with Turner syndrome. The Kabi Collaborative Study Group","volume":"35","author":"Job","year":"1991","journal-title":"Horm Res"},{"issue":"3-4","key":"2023091800470772700_dgad159-B28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000515875","article-title":"Safety and effectiveness of recombinant human growth hormone in children with Turner syndrome: data from the PATRO Children study","volume":"94","author":"Backeljauw","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"11","key":"2023091800470772700_dgad159-B29","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1210\/jcem.85.11.6976","article-title":"Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models.","volume":"85","author":"Ranke","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023091800470772700_dgad159-B30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1210\/jc.2009-1821","article-title":"Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome","volume":"95","author":"Menke","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023091800470772700_dgad159-B31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13633-015-0013-3","article-title":"Effect of oxandrolone therapy on adult height in Turner syndrome patients treated with growth hormone: a meta-analysis","volume":"2015","author":"Sheanon","year":"2015","journal-title":"Int J Pediatr Endocrinol"},{"key":"2023091800470772700_dgad159-B32","doi-asserted-by":"crossref","first-page":"d1980","DOI":"10.1136\/bmj.d1980","article-title":"Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial","volume":"342","author":"Gault","year":"2011","journal-title":"BMJ"},{"issue":"7","key":"2023091800470772700_dgad159-B33","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1210\/jc.2008-2094","article-title":"Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone","volume":"94","author":"Romano","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023091800470772700_dgad159-B34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40618-015-0418-0","article-title":"Efficacy and safety of growth hormone treatment in children with short stature: the Italian cohort of the GeNeSIS clinical study","volume":"39","author":"Cappa","year":"2015","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2023091800470772700_dgad159-B35","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0430","article-title":"Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting","volume":"177","author":"Gravholt","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2023091800470772700_dgad159-B36","author":"National Institute for Health and Care Excellence."},{"issue":"2","key":"2023091800470772700_dgad159-B37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.ijo.0801119","article-title":"Body mass index (BMI) in Turner syndrome before and during growth hormone (GH) therapy","volume":"24","author":"Blackett","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1","key":"2023091800470772700_dgad159-B38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cen.13044","article-title":"Weight gain in Turner syndrome: association to puberty induction?\u2014longitudinal analysis of KIGS data","volume":"85","author":"Reinehr","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"13","key":"2023091800470772700_dgad159-B39","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1056\/NEJMoa1005669","article-title":"Growth hormone plus childhood low-dose estrogen in Turner's syndrome","volume":"364","author":"Ross","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"2023091800470772700_dgad159-B40","doi-asserted-by":"crossref","first-page":"E1754","DOI":"10.1210\/jc.2013-4518","article-title":"Effects of low-dose estrogen replacement during childhood on pubertal development and gonadotropin concentrations in patients with Turner syndrome: results of a randomized, double-blind, placebo-controlled clinical trial","volume":"99","author":"Quigley","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023091800470772700_dgad159-B41","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jpeds.2015.08.036","article-title":"Attention-deficit\/hyperactivity disorder medication treatment impact on response to growth hormone therapy: results from the ANSWER program, a non-interventional study","volume":"167","author":"Rose","year":"2015","journal-title":"J Pediatr"},{"issue":"1","key":"2023091800470772700_dgad159-B42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000360005","article-title":"Stimulant use and its impact on growth in children receiving growth hormone therapy: an analysis of the KIGS International Growth Database","volume":"82","author":"Miller","year":"2014","journal-title":"Horm Res Paediatr"},{"issue":"Suppl 1","key":"2023091800470772700_dgad159-B43","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1530\/eje.0.151s055","article-title":"Lessons from the National Cooperative Growth Study","volume":"151","author":"Wyatt","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023091800470772700_dgad159-B44","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023091800470772700_dgad159-B45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1507\/endocrj.EJ11-0386","article-title":"An observational study of the effectiveness and safety of growth hormone (Humatrope\u00ae) treatment in Japanese children with growth hormone deficiency or Turner syndrome","volume":"60","author":"Tai","year":"2013","journal-title":"Endocr J"},{"issue":"3","key":"2023091800470772700_dgad159-B46","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.9778\/cmajo.20180020","article-title":"Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study","volume":"6","author":"Deal","year":"2018","journal-title":"CMAJ Open"},{"issue":"2","key":"2023091800470772700_dgad159-B47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s40124-013-0009-5","article-title":"Growth hormone and treatment controversy; long term safety of rGH","volume":"1","author":"Divall","year":"2013","journal-title":"Curr Pediatr Rep"},{"issue":"4","key":"2023091800470772700_dgad159-B48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/cen.13502","article-title":"Long-term safety of growth hormone\u2014a combined registry analysis","volume":"88","author":"Stochholm","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2023091800470772700_dgad159-B49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000435856","article-title":"Description of the SAGhE cohort: a large European study of mortality and cancer incidence risks after childhood treatment with recombinant growth hormone","volume":"84","author":"Swerdlow","year":"2015","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2023091800470772700_dgad159-B50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/jc.2018-01189","article-title":"Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 5","key":"2023091800470772700_dgad159-B51","first-page":"41","article-title":"Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database","volume":"68","author":"Darendeliler","year":"2007","journal-title":"Horm Res"},{"issue":"1","key":"2023091800470772700_dgad159-B52","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PLoS One"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad159\/50066561\/dgad159.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/10\/2653\/51533488\/dgad159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/10\/2653\/51533488\/dgad159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T06:33:19Z","timestamp":1702103599000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/10\/2653\/7083940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad159","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,3,22]]}}}